Key result
New preventive therapies for cardiovascular disease should establish equivalence or superiority to existing treatments in terms of all-cause mortality before widespread clinical use.
Answers are grounded in this paper and cite their sources.
Emphasizes that new preventive cardiovascular therapies should demonstrate equivalence or superiority in all-cause mortality before widespread use, rather than relying solely on surrogate endpoints.
Randomized controlled trials of therapies for the primary and secondary prevention of cardiovascular disease increasingly are powered to study overall mortality. The interventions frequently treat asymptomatic risk factors among high-risk patients and have a diverse spectrum of potential adverse effects. Thus, medications such as clofibrate or encainide that successfully alter surrogate end points but increase the rate of death are of little clinical interest. Many believe that a new preventive therapy for cardiovascular disease should be used sparingly, if at all, until clinical trials establish equivalence or even superiority to existing treatments in terms of mortality from all causes.When . . .
No takes yet. Share an insight, caveat, or question.
Wayne A. Ray (2005) conducted an editorial in Cardiovascular disease. New preventive therapies for cardiovascular disease should establish equivalence or superiority to existing treatments in terms of all-cause mortality before widespread clinical use.
Synapse has enriched 10 related papers. Consider them for comparative context: